Psychosis in Parkinson's and Alzheimer's Disease Market: Epidemiology, Pipeline Products, Companies, DelveInsight | Karuna Therapeutics, Sunovion Pharmaceuticals, Intra-Cellular Therapies, Acadia Phar

According to DelveInsight's analysis, the psychosis in Parkinson's disease and Alzheimer's disease market in the 7MM was valued at approximately USD 1,290 million in 2023 and is projected to grow over the forecast period from 2024 to 2034.
Emerging therapies for psychosis in Parkinson's and Alzheimer's disease, including NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others, are expected to drive significant growth in the market in the coming years.

DelveInsight has launched a new report on "Psychosis in Parkinson's and Alzheimer's Disease - Market Insights, Epidemiology, and Market Forecast-2034 [https://www.delveinsight.com/report-store/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" that delivers an in-depth understanding of the Psychosis in Parkinson's and Alzheimer's Disease, historical and forecasted epidemiology as well as the Psychosis in Parkinson's and Alzheimer's Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Psychosis in Parkinson's and Alzheimer's Disease Market Report:

*
According to DelveInsight, the psychosis market in Parkinson's disease and Alzheimer's disease across the seven major markets (7MM) was valued at approximately USD 1.29 billion in 2023 and is expected to grow steadily over the forecast period from 2024 to 2034.

*
In 2023, the total number of diagnosed Parkinson's disease cases in the 7MM was estimated at 2.6 million, with the United States accounting for about 45% of these cases. The EU4 (France, Germany, Italy, and Spain) and the UK together also represented roughly 45%, while Japan contributed around 10%. The prevalence of Parkinson's disease is projected to rise by 2034.

*
During the same year, an estimated 6.9 million diagnosed cases of psychosis associated with Parkinson's and Alzheimer's disease were reported in the 7MM. Among these, the United States accounted for 34%, Japan nearly 31%, and Germany around 11%.

*
The market for psychosis in these neurodegenerative diseases is expected to expand, driven by the launch of innovative therapies. Key emerging treatments include KarXT (xanomeline-trospium) by Karuna Therapeutics, Ulotaront (SEP-363856) by Sunovion Pharmaceuticals, and ITI-1284 by Intra-Cellular Therapies.

*
With the aging population growing, the prevalence of Parkinson's and Alzheimer's disease is expected to increase, fueling demand for effective psychosis treatments. Greater awareness of psychosis as a significant symptom may lead to earlier diagnosis and better management, further supporting market growth.

*
However, substantial unmet needs remain. The lack of curative therapies and reliable biomarkers makes early diagnosis and treatment challenging. Existing screening tools are often complex, and while NUPLAZID (pimavanserin) is approved for psychosis in Parkinson's disease, there is no FDA-approved treatment for psychosis in Alzheimer's disease, highlighting a critical gap. Additionally, psychosis symptoms are often underreported or misattributed, causing delays in care and inaccuracies in epidemiological data.

*
Key companies actively developing therapies in this space include Karuna Therapeutics, Sunovion Pharmaceuticals, Intra-Cellular Therapies, Acadia Pharmaceuticals, and others. Promising pipeline candidates include NUPLAZID, Ulotaront, KarXT, ITI-1284, among others.

*
In May 2023, the FDA approved Rexulti (brexpiprazole) for treating agitation associated with dementia due to Alzheimer's disease. This marked the first FDA-approved therapy addressing restlessness and aggression in Alzheimer's patients. Clinical trials showed that patients receiving 2 mg or 3 mg of Rexulti experienced significant symptom improvements compared to placebo, with common side effects including headache, dizziness, urinary tract infections, and sleep disturbances.

Key benefits of the Psychosis in Parkinson's and Alzheimer's Disease market report:

*
Psychosis in Parkinson's and Alzheimer's Disease market report covers a descriptive overview and comprehensive insight of the Psychosis in Parkinson's and Alzheimer's Disease Epidemiology and Psychosis in Parkinson's and Alzheimer's Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

*
The Psychosis in Parkinson's and Alzheimer's Disease market report provides insights on the current and emerging therapies.

*
Psychosis in Parkinson's and Alzheimer's Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Psychosis in Parkinson's and Alzheimer's Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Psychosis in Parkinson's and Alzheimer's Disease market.

Got queries? Click here to know more about the Psychosis in Parkinson's and Alzheimer's Disease Market Landscape [https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr].

Psychosis in Parkinson's and Alzheimer's Disease Overview

According to the National Institute of Mental Health (NIMH), psychosis is a group of symptoms that interfere with an individual's perception of reality, causing a disconnection from the real world. During a psychotic episode, a person's thoughts and perceptions are distorted, making it difficult to differentiate between what is real and what is not.

Psychosis is generally divided into three main types: idiopathic psychosis, psychosis resulting from medical conditions (such as neurodegenerative disorders), and toxic psychosis, which arises from substance use, medications, or exposure to toxins. It is a symptom complex that can occur in various disorders, including Alzheimer's disease (AD) and Parkinson's disease (PD), where severe psychotic manifestations may develop.

In Parkinson's disease psychosis (PDP), patients often experience visual hallucinations, along with other symptoms such as auditory hallucinations, delusions, illusions, depression, and anxiety. PDP is linked to higher morbidity and mortality, decreased engagement in health-promoting behaviors, and an increased risk of long-term care placement. Similarly, Alzheimer's disease psychosis (ADP) frequently occurs in individuals with AD, presenting with dementia, auditory and visual hallucinations, and progressive cognitive decline. These symptoms worsen over time, substantially affecting both life expectancy and quality of life.

Psychosis in Parkinson's and Alzheimer's Disease Market Outlook [https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Psychosis frequently occurs in individuals with Alzheimer's disease and often persists throughout the course of the illness. Studies indicate that over half of Alzheimer's patients will experience psychotic symptoms at some point during their disease progression.

Antipsychotic medications remain the primary treatment for managing psychotic episodes, with drug choice, dosage, and administration tailored to the specific condition. Alongside pharmacological therapy, caregivers and family members play a vital role in managing psychosis by providing a safe and supportive environment. Cognitive behavioral therapy (CBT) is also commonly recommended as an initial intervention for individuals exhibiting psychotic symptoms.

Although standardized treatment guidelines are limited, pimavanserin (34 mg/day) is considered first-line therapy for Parkinson's disease psychosis, as it is the only FDA-approved drug for this condition and has a low risk of severe adverse effects. If pimavanserin is unavailable or ineffective, clozapine (up to 50 mg/day) or quetiapine (titrated up to 150 mg/day) may be used. However, quetiapine may not fully control psychotic symptoms in some patients, while clozapine carries the risk of agranulocytosis and requires regular blood monitoring.

There is a pressing need for more effective and targeted therapies for psychosis in both Alzheimer's and Parkinson's disease, as current treatments are often limited by side effects such as hallucinations, confusion, and nausea. With no FDA-approved therapy for Alzheimer's disease psychosis, developing precise risk profiles and optimizing the use of existing antipsychotics remain critical objectives.

To address these unmet needs, several late-stage drug candidates are under development. These include KarXT (xanomeline-trospium) by Karuna Therapeutics, Ulotaront (SEP-363856) by Sunovion Pharmaceuticals, and FANAPT (iloperidone), all of which show promise in expanding treatment options for psychosis associated with neurodegenerative diseases.

Psychosis in Parkinson's and Alzheimer's Disease Marketed Drugs

*
NUPLAZID (pimavanserin): Acadia Pharmaceuticals

Psychosis in Parkinson's and Alzheimer's Disease Emerging Drugs

*
Ulotaront (SEP-363856): Sunovion Pharmaceuticals

*
KarXT (xanomeline-trospium): Karuna Therapeutics

*
ITI-1284: Intra-Cellular Therapies

Scope of the Psychosis in Parkinson's and Alzheimer's Disease Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Psychosis in Parkinson's and Alzheimer's Disease Companies [https://www.delveinsight.com/report-store/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]: Karuna Therapeutics, Sunovion Pharmaceuticals, Intra-Cellular Therapies, Acadia Pharmaceuticals, and others

*
Key Psychosis in Parkinson's and Alzheimer's Disease Therapies: NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others

*
Psychosis in Parkinson's and Alzheimer's Disease Therapeutic Assessment: Psychosis in Parkinson's and Alzheimer's Disease current marketed and Psychosis in Parkinson's and Alzheimer's Disease emerging therapies

*
Psychosis in Parkinson's and Alzheimer's Disease Market Dynamics: Psychosis in Parkinson's and Alzheimer's Disease market drivers and Psychosis in Parkinson's and Alzheimer's Disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Psychosis in Parkinson's and Alzheimer's Disease Unmet Needs, KOL's views, Analyst's views, Psychosis in Parkinson's and Alzheimer's Disease Market Access and Reimbursement

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Psychosis in Parkinson's and Alzheimer's Disease Patient Share (%) Overview at a Glance

5. Psychosis in Parkinson's and Alzheimer's Disease Market Overview at a Glance

6. Psychosis in Parkinson's and Alzheimer's Disease Disease Background and Overview

7. Psychosis in Parkinson's and Alzheimer's Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Psychosis in Parkinson's and Alzheimer's Disease

9. Psychosis in Parkinson's and Alzheimer's Disease Current Treatment and Medical Practices

10. Unmet Needs

11. Psychosis in Parkinson's and Alzheimer's Disease Emerging Therapies

12. Psychosis in Parkinson's and Alzheimer's Disease Market Outlook

13. Country-Wise Psychosis in Parkinson's and Alzheimer's Disease Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Psychosis in Parkinson's and Alzheimer's Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Psychosis in Parkinson's and Alzheimer's Disease Market Outlook 2034 [https://www.delveinsight.com/report-store/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr].

Related Reports:

Psychosis in Parkinson's and Alzheimer's Disease Pipeline Insights, DelveInsight

"Psychosis in Parkinson's and Alzheimer's Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Psychosis in Parkinson's and Alzheimer's Disease market. A detailed picture of the Psychosis in Parkinson's and Alzheimer's Disease pipeline landscape is provided, which includes the disease overview and Psychosis in Parkinson's and Alzheimer's Disease treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=psychosis-in-parkinsons-and-alzheimers-disease-market-epidemiology-pipeline-products-companies-delveinsight-karuna-therapeutics-sunovion-pharmaceuticals-intracellular-therapies-acadia-phar]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.